Pre-made Varisacumab benchmark antibody ( Whole mAb, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Varisacumab (GNR 011), a biosimilar of bevacizumab [see Adis Insight Drug profile 800008086] is under development with International Biotech Center Generium (IBC Generium), for the treatment of various types of cancer, including colorectal, non-small cell lung, glioblastoma and breast cancer, and ophthalmic conditions.
| Products Name (INN Index) | Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody |
|---|---|
| INN Name | Varisacumab |
| Target | VEGFA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Peregrine Pharmaceuticals,University of Texas Southwestern Medical Center,Affitech Research AS |
| Conditions Approved | NA |
| Conditions Active | Breast cancer,Colorectal cancer,Eye disorders,Glioblastoma,Non-small cell lung cancer |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | VEGFA |
| Package |
